Ces radiol. 2019, 73(3):177-182 | DOI: 10.55095/CesRadiol2019/026

Radionuclide imaging of central nervous systemReview article

Jiří Doležal, Eva Krčálová
Oddělení nukleární medicíny LF UK a FN Hradec Králové

Aim: The article provides an overview of current radionuclide brain imaging modalities including scintigraphy, SPECT and PET. Review summarizes the key areas of their applications.

Method: SPECT brain perfusion imaging, SPECT presynaptic dopamine transporters assessment and PET metabolic brain imaging methods disclosing not only brain glucose metabolism (using 18F-FDG), but also DNA synthesis in high-grade gliomas (18F-FLT), tumour hypoxia (using 18FMISO) and β-amyloid neuritic plaques deposition in patients with m. Alzheimer are described as well as radionuclide cisternography.

Results: Aforementioned methods performed at our department are presented via enclosed scintigrams.

Conclusion: Radionuclide brain imaging methods plays an important role in managing patients with brain diseases, such as cerebrovascular disease, dementias, m. Parkinson, m. Alzheimer and brain tumours. Radionuclide brain imaging methods (particularly PET tumour imaging) enable us to provide diagnosis, prognosis and evaluate treatment response.

Keywords: brain imaging, scintigraphy, SPECT, PET
Grants and funding:

Podpořeno MZ ČR - RVO (FNHK 00179906).

Accepted: September 15, 2019; Published: September 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Doležal J, Krčálová E. Radionuclide imaging of central nervous system. Ces radiol. 2019;73(3):177-182. doi: 10.55095/CesRadiol2019/026.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Koranda P, Kamínek M, Ptáček J, Mysliveček M, et al. Nukleární medicína. Olomouc: Univerzita Palackého 2014.
    2. Morton KA, Clark PB, Blodgett TM, Christensen CR, et al. Diagnostic Imaging: Nuclear Medicine. Salt Lake City, Utah: Amirsys 2007.
    3. Bennett P, Oza UD, Trout AT, Mintz A, et al. Diagnostic Imaging: Nuclear Medicine, 2nd edition. Philadelphia, USA: Elsevir 2016.
    4. Ziessman HA, O'Malley JP, Thrall JH, Fahey FH. Nuclear medicine. 4th edition. Philadelphia, USA: Elsevier/Saunders 2014.
    5. Heiss WD. Radionuclide Imaging in Ischemia Stroke. J Nucl Med 2014; 55(11): 1831-1841. Go to original source... Go to PubMed...
    6. Nichols KJ, Chen B, Tomas MB, Palestro CJ. Interpreting 123I-ioflupane dopamine transporter scans using hybrid scores. Eur J Hybrid Imaging 2018; 2(1): 10. doi:10.1186/s41824-018-0028-0 Go to original source... Go to PubMed...
    7. Djang DSW, Janssen MJR, Bohnen N, Booij J, et al. SNM Practise Guideline for Dopamine Transporter Imaging with 123I-ioflupane SPECT 1.0. J Nucl Med 2012; 53(1): 154-163. Go to original source... Go to PubMed...
    8. Costa DC, Walker Z, Walker RW, Fontes FR. Dementia with Lewy bodies versus Alzheimer's disease: role of dopamine transporter imaging. Mov Disord 2003;18(Suppl 7): S34-38. Go to original source... Go to PubMed...
    9. Shivamurthy VKN, Tahari AK, Marcus C, Subramaniam RM. Brain FDG PET and the Diagnosis of Dementia. AJR Am J Roentgenol 2015; 204(1): 76-85. Go to original source... Go to PubMed...
    10. Leiva-Salinas C, Muttikkal TJE, Flors L, Puig J,et al. FDG PET/MRI Coregistration Helps Predict Response to Gamma Knife Radiosurgery in Patients with Brain Metastases. AJR Am J Roentgenol 2018; Nov 13: 1-6. doi:10.2214/AJR.18.20006 Go to original source... Go to PubMed...
    11. Ferdová E, Ferda J, Baxa J, et al. Assessment of grading in newly-diagnosed glioma using 18F-fluorothymidine PET/CT. Anticancer Res 2015; 35(2): 955-959.
    12. Ferda J, Ferdová E, Baxa J, et al. Lekce z molekulárního zobrazování: hodnocení mozkových nádorů pomocí PET/MR. Ces Radiol 2016; 70(4): 205-218. Go to original source...
    13. Ferda J, Ferdová E, Hes O, Mráček J, et al. PET/MRI: Multiparametric imaging of brain tumors. Eur J Radiol 2017; 94: 14-25. doi:10.1016/j.ejrad.2017.02.034. Go to original source... Go to PubMed...
    14. Nandu H, Wen PY, Huang RY. Imaging in neuro-oncology. Ther Adv Neurol Disord 2018; 11: 1756286418759865. doi:10.1177/1756286418759865 Go to original source... Go to PubMed...
    15. Brahm CG, den Hollander MW, Enting RH, et al. Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study. Eur J Nucl Med Mol Imaging 2018; 45(13): 2404-2412. Go to original source... Go to PubMed...
    16. Gerbaudo VH, et al. A case based approach to PET/CT in Oncology. New York: Cambridge University Press 2012; 24-25. Go to original source...
    17. Barajas RF, Krohn KA, Link JM, Hawkins RA, et al. Glioma FMISO PET/MR imaging concurrent with antiangiogenic therapy: Molecular imaging as a clinical tool in the burgeoning era of personalized medicine. Biomedicines 2016; 4(4): E24. doi:10.3390/biomedicines4040024 Go to original source... Go to PubMed...
    18. Gerstner ER, Zhang Z, Fink JR, Muzi M,et al. ACRIN 6684: assessment of tumor hypoxia in newly diagnosed glioblastoma using 18F-FMISO PET and MRI. Clin Cancer Res 2016; 22(20): 5079-5086. Go to original source... Go to PubMed...
    19. Szeto MD, Chakraborty G, Hadley J, Rockne R, et al. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. J Cancer Res 2009; 69(15): 4502-4509. Go to original source... Go to PubMed...
    20. Grothe MJ, Barthel H, Sepulcre J, Dyrba M, et al. In vivo staging of regional amyloid deposition. Neurology 2017; 89(20): 2031-2038. Go to original source... Go to PubMed...
    21. Lao PJ, Brickman AM. Multimodal neuroimaging study of cerebrovascular disease, amyloid deposition, and neurodegeneration in Alzheimer's disease progression. Alzheimers Dement (Amst) 2018; 10: 638-646. doi:10.1016/j.dadm.2018.08.007 Go to original source... Go to PubMed...
    22. Florek L, Tiepolt S, Schroeter ML, Berrouschot J, et al. Dual time-point (18F) florbetaben PET delivers dual biomerker information in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 2018; 66(3): 1105-1116. Go to original source... Go to PubMed...
    23. Lundeen TF, Seibyl JP, Covington MF, Eshghi N,et al. Signs and artefacts in amyloid PET. Radiographics 2018; 38(7): 2123-2133. Go to original source... Go to PubMed...
    24. Luetmer PH, Huston J, Friedman JA, Dixon GR, et al. Measurement of cerebrospinal fluid flow at the cerebral aqueduct by use of phase-contrast magnetic resonance imaging: technique validation and utility in diagnosing idiopathic normal pressure hydrocephalus. Neurosurgery 2002; 50(3): 534-544. Go to original source...
    25. Choi EK, Oh JK, Park SY, Yoo I, et al. Visual and quantitative analysis of cisternography for the detection of cerebrospinal fluid leakage. Nucl Med Mol Imaging 2017; 51(2): 193-194. Go to original source... Go to PubMed...
    26. Bulman JC, Wachsmann J, Peng F, et al. Asymmetric radiotracer activity of enlarged cerebral spinal fluid space on radionuclide cisternography with SPECT/CT. Hell J Nucl Med 2016; 19(3): 269-271.
    27. Kazumata K, Mamiyama H, Ishikawa T, Makino K, et al. Clinical study of cerebrospinal fluid dynamics using 111In-DTPA SPECT in patients with subarochnoid hemorrhage. Neurol Med Chir (Tokyo) 2006; 46(1): 11-18. Go to original source... Go to PubMed...
    28. Vybíhal V. Chirurgická léčba hydrocefalu. Cesk Slov Neurol N 2014; 77/110(1): 7-22.

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content